213 related articles for article (PubMed ID: 20428808)
1. Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors.
Wu K; Zeng J; Li L; Fan J; Zhang D; Xue Y; Zhu G; Yang L; Wang X; He D
Oncol Rep; 2010 Jun; 23(6):1545-52. PubMed ID: 20428808
[TBL] [Abstract][Full Text] [Related]
2. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
[TBL] [Abstract][Full Text] [Related]
3. Silibinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cells.
Thelen P; Jarry H; Ringert RH; Wuttke W
Planta Med; 2004 May; 70(5):397-400. PubMed ID: 15124082
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells.
Thelen P; Wuttke W; Jarry H; Grzmil M; Ringert RH
J Urol; 2004 May; 171(5):1934-8. PubMed ID: 15076315
[TBL] [Abstract][Full Text] [Related]
5. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression.
Wu KJ; Zeng J; Zhu GD; Zhang LL; Zhang D; Li L; Fan JH; Wang XY; He DL
Acta Pharmacol Sin; 2009 Aug; 30(8):1162-8. PubMed ID: 19578386
[TBL] [Abstract][Full Text] [Related]
6. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.
Chu SC; Chiou HL; Chen PN; Yang SF; Hsieh YS
Mol Carcinog; 2004 Jul; 40(3):143-9. PubMed ID: 15224346
[TBL] [Abstract][Full Text] [Related]
7. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression.
Huber MA; Azoitei N; Baumann B; Grünert S; Sommer A; Pehamberger H; Kraut N; Beug H; Wirth T
J Clin Invest; 2004 Aug; 114(4):569-81. PubMed ID: 15314694
[TBL] [Abstract][Full Text] [Related]
8. NF-kappaB and epithelial to mesenchymal transition of cancer.
Min C; Eddy SF; Sherr DH; Sonenshein GE
J Cell Biochem; 2008 Jun; 104(3):733-44. PubMed ID: 18253935
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-1alpha induces the epithelial-mesenchymal transition of human prostatecancer cells.
Luo Y; He DL; Ning L; Shen SL; Li L; Li X
Chin Med J (Engl); 2006 May; 119(9):713-8. PubMed ID: 16701010
[TBL] [Abstract][Full Text] [Related]
10. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of transcription factors repressing epithelial phenotype in two different prostate cancer EMT models and its significance].
Wu KJ; Zeng J; Zhu GD; Zhang D; Xue Y; Chen YL; Wang XY; He DL
Zhonghua Nan Ke Xue; 2010 Feb; 16(2):137-41. PubMed ID: 20369697
[TBL] [Abstract][Full Text] [Related]
12. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells.
Zi X; Zhang J; Agarwal R; Pollak M
Cancer Res; 2000 Oct; 60(20):5617-20. PubMed ID: 11059749
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of silibinin on the viability, migration and adhesion of the human prostate adenocarcinoma (PC-3) cell line.
Mokhtari MJ; Motamed N; Shokrgozar MA
Cell Biol Int; 2008 Aug; 32(8):888-92. PubMed ID: 18538589
[TBL] [Abstract][Full Text] [Related]
14. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer chemoprevention by silibinin: bench to bedside.
Singh RP; Agarwal R
Mol Carcinog; 2006 Jun; 45(6):436-42. PubMed ID: 16637061
[TBL] [Abstract][Full Text] [Related]
16. A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells.
Liu H; Chen A; Guo F; Yuan L
Cancer Lett; 2010 Sep; 295(1):27-37. PubMed ID: 20207476
[TBL] [Abstract][Full Text] [Related]
17. Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression.
Uzzo RG; Crispen PL; Golovine K; Makhov P; Horwitz EM; Kolenko VM
Carcinogenesis; 2006 Oct; 27(10):1980-90. PubMed ID: 16606632
[TBL] [Abstract][Full Text] [Related]
18. Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness.
Wu K; Ning Z; Zeng J; Fan J; Zhou J; Zhang T; Zhang L; Chen Y; Gao Y; Wang B; Guo P; Li L; Wang X; He D
Cell Signal; 2013 Dec; 25(12):2625-33. PubMed ID: 24012496
[TBL] [Abstract][Full Text] [Related]
19. VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop.
Gonzalez-Moreno O; Lecanda J; Green JE; Segura V; Catena R; Serrano D; Calvo A
Exp Cell Res; 2010 Feb; 316(4):554-67. PubMed ID: 20006606
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.
Tyagi A; Bhatia N; Condon MS; Bosland MC; Agarwal C; Agarwal R
Prostate; 2002 Nov; 53(3):211-7. PubMed ID: 12386921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
